

PDAC'S AUTOGRAPH:

Detecting Early Stage Pancreatic Cancer Using A Biomarker Signature

A Breakfast Seminar | Tuesday, October 16, 2018 | 7:00–7:50 AM

Protein kinase C zeta type
Interferon gamma
Cyclin-dependent kinase-2
Visual system homeobox-2
Lymphotoxin-alpha
Intercellular adhesion molecule-1
Calcineurin B homologous protein-1
Interleukin-4 Properdin
Apolipoprotein-A1
Myomesin-2 Protein-tyrosine kinase-6
Vascular endothelial growth factor HADH2-protein Serine/threonine-protein kinase MARK1
Aprataxin/PNK-like factor Plasma protease C1 inhibitor
Membrane-associated guanylate kinase WW/PDZ domain-containing protein-1
Calcium/calmodulin-dependent protein kinase type-IV
Lewis x Complement-C3 Sialyl Lewis x
Interleukin-6 PR domain zinc finger protein-8
Complement-C4
Complement-C5
Disk large homolog-1
GTP-binding protein GEM
Interleukin-13



PDAC'S AUTOGRAPH:

Detecting Early Stage Pancreatic Cancer Using A Biomarker Signature

A Breakfast Seminar

Date: Tuesday, October 16, 2018

Time: 7:00 – 7:50 AM

Location: Indigo 202
Hilton San Diego Bayfront

Presenter: **Thomas King, MD, PhD**
Medical Director
Immunovia, Inc.
Marlborough, Massachusetts

Adjunct Associate Professor
School of Health Professions
Rutgers, The State University of New Jersey
Newark, New Jersey

AGENDA:

- 7:00 AM *Promising Data from a Serum Biomarker Signature for the Early Detection of Pancreatic Cancer*
- 7:20 *The IMMray® Platform: How it Works and its Clinical Application*
- 7:40 **Question & Answer Session**
- 7:50 **Seminar Conclusion**



Click here to register



www.immunovia.com

IMMray is a registered trademark of Immunovia, Inc.

QUESTIONS? Contact Carrie Mansfield at carrie.mansfield@immunovia.com | (203) 984-5051